Polaryx Therapeutics, Inc. (PLYX) shares surged 77.18%, trading at $4.2700, up $1.8600, after the company announced it has selected a contract research organization or CRO, for its Phase 2 SOTERIA trial.
The company said selecting a CRO is a key milestone in advancing its lead candidate PLX-200, with the partner bringing experience in rare disease trials and establishing ties with key opinion leaders and patient groups.
The Phase 2 SOTERIA study is an open label, single arm basket trial evaluating PLX-200 across four lysosomal storage disorders. The company received FDA clearance in October 2025 and plans to begin the trial in the first half of 2026.
Polaryx said the flexible trial design could support future pivotal studies and potential conditional approvals if clinical results are positive.
On the day of the announcement, PLYX traded between $3.0900 and $5.0500. Trading volume was 47,124,379 shares compared with an average of 169,480 shares. Polaryx's 52 week range is $2.2000 to $48.9100.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.